Pharmaceuticals

Targeted LNPs for Extrahepatic Delivery Market Forecast to Hit $4.67 Billion by 2030

April 8, 2026April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Targeted LNPs For Extrahepatic Delivery Market By The End Of 2030?

The market size for targeted LNPs for extrahepatic delivery has experienced significant expansion in recent years. Projections indicate this market will increase from $1.81 billion in 2025 to $2.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.7%. The historical growth can be linked to the achievements of hepatic LNP delivery systems, the rise of mRNA vaccine platforms, the broadening of nanomedicine research, an uptick in gene therapy trials, and the increasing complexities in biologic drug delivery.

The targeted lnps for extrahepatic delivery market is anticipated to experience rapid expansion over the coming years. This market is projected to reach $4.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.9%. Factors contributing to this expansion during the projection period include the expanding development of RNA therapeutics, a heightened need for tissue-specific delivery, the proliferation of precision drug delivery systems, intensified research into oncology nanoparticles, and an increase in biotech delivery collaborations. Key trends anticipated within the forecast timeframe encompass LNP formulations designed for extrahepatic targeting, nanoparticle delivery guided by ligands, RNA delivery systems tailored for specific tissues, innovative ionizable lipid constructions, and adaptable targeted nanocarrier architectures.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33338&type=smp

What Major Drivers Are Influencing Demand In The Targeted LNPs For Extrahepatic Delivery Market?

The anticipated growth of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market is driven by the increasing need for personalized medicine (PM). Personalized medicine involves treatments specifically designed for an individual’s genetic makeup, disease features, or biomarkers to achieve maximum treatment success and reduce adverse effects. The uptake of personalized therapies is accelerating due to progress in molecular diagnostics, the discovery of biomarkers, and the development of precision drugs. Targeted lipid nanoparticles are essential for personalized medicine as they allow for the exact delivery of therapeutic agents to particular tissues or cell types, including extrahepatic sites, thereby boosting therapeutic efficacy and safety. An example illustrating this trend is provided by the Personalized Medicine Coalition, which reported that the U.S. Food and Drug Administration sanctioned 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the escalating demand for personalized medicine (PM) is propelling the expansion of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market.

Which Segment Classifications Shape The Targeted LNPs For Extrahepatic Delivery Market?

The targeted lnps for extrahepatic delivery market covered in this report is segmented –

1) By Product Type: Ionizable Lipid-Based Lipid Nanoparticles; Cationic Lipid-Based Lipid Nanoparticles; Polyethylene Glycol-Coated Lipid Nanoparticles; Other Lipid Nanoparticle Formulations

2) By Therapeutic Area: Oncology; Infectious Diseases; Genetic Disorders; Metabolic Diseases; Other Therapeutic Area

3) By Application: Gene Therapy; Messenger Ribonucleic Acid Vaccines; Small Interfering Ribonucleic Acid Delivery; Protein Delivery; Other Application

4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic and Research Institutes; Other End-Users

Subsegments:

1) By Ionizable Lipid-Based Lipid Nanoparticles: Single Chain Ionizable Lipids; Multi-Chain Ionizable Lipids; Functionalized Ionizable Lipids

2) By Cationic Lipid-Based Lipid Nanoparticles: Quaternary Ammonium Cationic Lipids; Permanent Cationic Lipids; Helper Lipids in Cationic Formulations

3) By Polyethylene Glycol-Coated Lipid Nanoparticles: Polyethylene Glycolylated Lipids with Different Chain Lengths; Polyethylene Glycol-Lipid Conjugates with Targeting Ligands; Polyethylene Glycolylated Lipid Combinations for Stability

4) By Other Lipid Nanoparticle Formulations: Sphingomyelin-Based Lipid Nanoparticles; Biodegradable Lipid Nanoparticles; Modular or Hybrid Lipid Nanoparticles; Stimulus-Responsive Lipid Nanoparticles

How Are Trends Impacting The Targeted LNPs For Extrahepatic Delivery Market?

Leading companies in the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market are concentrating on technological enhancements within targeted LNP platforms, including DARPin-conjugated systems, to achieve more selective delivery to immune and tissue-specific cells. DARPin-conjugated lipid nanoparticles are described as LNPs functionalized with Designed Ankyrin Repeat Proteins (DARPins), which are engineered binding proteins capable of highly specific interactions with particular cell surface receptors. This targeting capability enables improved uptake by specific cell types, supporting extrahepatic applications such as immune cell modulation and tissue-specific gene delivery. For instance, in November 2025, Acuitas Therapeutics Inc., a Canada-based biotechnology company, launched next-generation LNP technologies designed for extrahepatic targeting. These included platforms for T-lymphocyte delivery, mucous-penetrant formulations for airway epithelial cells, and a pre-formed vesicle manufacturing approach intended to enhance scalability, cost efficiency, and storage stability. These advancements extend the potential applications of mRNA-LNP therapeutics beyond the liver, supporting broader uses in gene editing, vaccines, and personalized medicine.

Which Companies Hold Significant Positions In The Targeted LNPs For Extrahepatic Delivery Market?

Major companies operating in the targeted lnps for extrahepatic delivery market are Pfizer Inc., Sanofi S.A., Merck KGaA, FUJIFILM Pharmaceuticals U.S.A. Inc., Evonik Industries AG, Recipharm, CordenPharma International GmbH, Ardena Nanomedicines, Arcturus Therapeutics Holdings Inc., BIOVECTRA Inc., Ascendia Pharmaceuticals Inc., ABITEC Corporation, Creative Biolabs, Genevant Sciences GmbH, Polymun Scientific Immunbiologische Forschung GmbH, ST Pharm, eTheRNA immunotherapies NV, NanoVation Therapeutics, DIANT Pharma, Curapath, Phosphorex Inc.

Read the full targeted lnps for extrahepatic delivery market report here:

https://www.thebusinessresearchcompany.com/report/targeted-lnps-for-extrahepatic-delivery-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Targeted LNPs For Extrahepatic Delivery Market?

North America was the largest region in the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted lnps for extrahepatic delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Targeted LNPs For Extrahepatic Delivery Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33338&type=smp

Browse Through More Reports Similar to the Global Targeted LNPs For Extrahepatic Delivery Market 2026, By The Business Research Company

Liver Health Supplements Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-health-supplements-global-market-report

Liver Diseases Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Fatty Liver Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795